Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

STOP‐AD portal: Selecting the optimal pharmaceutical for preclinical drug testing in Alzheimer's disease

STOP‐AD portal: Selecting the optimal pharmaceutical for preclinical drug testing in Alzheimer's... INTRODUCTIONGiven the mounting human health and economic costs, coupled with the rapidly rising number of Alzheimer's disease (AD) cases worldwide, there is a desperate need to develop therapeutics that can treat, delay, or prevent AD.1 Despite the herculean efforts over the past 20 years to develop disease‐modifying treatments for AD, only two of the more than 400 disease modifying interventions tested to date has gained FDA approval.2 While a wide variety of potential causes of these failures have been proposed2 the lack of translation to the clinic from preclinical efficacy experiments has been thought to contribute significantly.3,4To this end, and to aid in the acceleration of developing treatments for AD, the National Institutes of Aging (NIA) AD Research Summit of 2015 provided a list of recommendations aimed at increasing the predictive value of AD animal models and enabling transparent and reproducible preclinical efficacy testing.5 As a result of these recommendations, the Model Organism Development and Evaluation for Late‐Onset Alzheimer's Disease (MODEL‐AD) consortium was established.6 The overarching aims of this program are to (1) design, develop, and characterize new mouse models for late‐onset AD (LOAD); and (2) establish a preclinical testing core (PTC) that establishes and implements pharmaceutical testing in http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Alzheimer s & Dementia Wiley

STOP‐AD portal: Selecting the optimal pharmaceutical for preclinical drug testing in Alzheimer's disease

Loading next page...
 
/lp/wiley/stop-ad-portal-selecting-the-optimal-pharmaceutical-for-preclinical-8Rm9yIoehs

References (26)

Publisher
Wiley
Copyright
© 2023 the Alzheimer's Association.
ISSN
1552-5260
eISSN
1552-5279
DOI
10.1002/alz.13108
Publisher site
See Article on Publisher Site

Abstract

INTRODUCTIONGiven the mounting human health and economic costs, coupled with the rapidly rising number of Alzheimer's disease (AD) cases worldwide, there is a desperate need to develop therapeutics that can treat, delay, or prevent AD.1 Despite the herculean efforts over the past 20 years to develop disease‐modifying treatments for AD, only two of the more than 400 disease modifying interventions tested to date has gained FDA approval.2 While a wide variety of potential causes of these failures have been proposed2 the lack of translation to the clinic from preclinical efficacy experiments has been thought to contribute significantly.3,4To this end, and to aid in the acceleration of developing treatments for AD, the National Institutes of Aging (NIA) AD Research Summit of 2015 provided a list of recommendations aimed at increasing the predictive value of AD animal models and enabling transparent and reproducible preclinical efficacy testing.5 As a result of these recommendations, the Model Organism Development and Evaluation for Late‐Onset Alzheimer's Disease (MODEL‐AD) consortium was established.6 The overarching aims of this program are to (1) design, develop, and characterize new mouse models for late‐onset AD (LOAD); and (2) establish a preclinical testing core (PTC) that establishes and implements pharmaceutical testing in

Journal

Alzheimer s & DementiaWiley

Published: Nov 1, 2023

Keywords: Alzheimer's disease; drug development; drug selection; preclinical models

There are no references for this article.